SCHEMBL6843239

SCHEMBL6843239

O=C(O)c1cc(Oc2ccc3ccccc3c2)cc(C(=O)O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.58
SIRT2 Q8IXJ6 1/20 0.55
SIRT1 Q96EB6 1/20 0.55
SIRT3 Q9NTG7 1/20 0.55
KMT2A Q03164 5/20 0.54
MEN1 O00255 4/20 0.54
MAPT P10636 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.52
MRGPRX4 Q96LA9 1/20 0.51
PTPN7 P35236 1/20 0.50
KMO O15229 1/20 0.49
SRD5A2 P31213 1/20 0.49
KDM4E B2RXH2 2/20 0.47
FLT3 P36888 1/20 0.47
MCL1 Q07820 1/20 0.47
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6405694 0.87 SRD5A2 (0.65) AKR1C3SIRT2SIRT1SIRT3KMT2A
SCHEMBL6840897 0.86 PTGS2 (0.55) AKR1C3SIRT2SIRT1SIRT3KMT2A
Bicarbonate SCHEMBL27942180 0.85 KMT2A (0.60) SIRT2SIRT1SIRT3KMT2AMEN1
SCHEMBL1768785 0.83 AKR1C3 (0.74) AKR1C3KMT2AMEN1KMOSRD5A2
SCHEMBL29779473 0.82 KMT2A (0.65) AKR1C3KMT2AMEN1MAPTKMO
SCHEMBL6840894 0.81 SIRT2 (0.51) SIRT2SIRT1SIRT3KMT2AMEN1
SCHEMBL18545874 0.79 KDM4E (0.67) AKR1C3KMT2AMEN1MAPTTDP1
SCHEMBL8081668 0.79 MAPT (0.60) KMT2AMEN1MAPTTDP1MRGPRX4
SCHEMBL21652693 0.79 PARP10 (0.64) AKR1C3KMT2AMEN1MAPTL3MBTL1
SCHEMBL5747830 0.79 AKR1C3 (0.74) AKR1C3KMT2AMEN1KMOSRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157919-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use WU YONG-QIAN (US) 2004-08-12 US disclosed
US-6656971-B2 Non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilins; inhibiting their peptidyl-prolyl isomerase activity; treating variety of medical conditions GUILFORD PHARMACEUTICALS INC. 2003-12-02 US disclosed
EP-1360173-A2 TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE GUILFORD PHARMACEUTICALS INC. (US) 2003-11-12 EP disclosed
US-20020165275-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use GUILFORD PHARMACEUTICALS INC. 2002-11-07 US disclosed
WO-2002059080-A2 TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE GUILFORD PHARMACEUTICALS INC. (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157919-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use FKBP2, PPIG, FKBP8 AKR1C3 524/4885SIRT2 4155/4885SIRT1 4126/4885
US-20020165275-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use FKBP2, PPIG, FKBP8 AKR1C3 524/4885SIRT2 4155/4885SIRT1 4126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.